文献库搜索 | GeneLibs

Monda(SM),Oh(E),Lewicki(PJ),Kaffenberger(S... Eur Urol Open Sci 2026-04-00

...BRCA1 and BRCA2, among others) variants, comparing with an institutional cohort of MMR carriers (n = 35; 2012-2025). We ...

Tezuka(H),Matsui(A),Murata(Y),Odani(E),Tsu... Cureus 2026-03-00

...BRCA1/2 variants. This report highlights an extremely rare, pathologically confirmed case of synchronous bilateral prima...

Marek-Yagel(D),Greenberg(R),Naftali(M),Ben... J Mol Diagn 2026-06-00

...BRCA1, BRCA2, and PALB2, whereas LDLR and TPM1 remained largely unchanged. No consistent correlation was found between t...

Lønning(PE),Nikolaienko(O),Knappskog(S) Breast Cancer Res 2026-04-17

...BRCA1 deficiency to the development of ER+ breast cancers in gBRCA1 carriers is incompletely understood. BRCA1 epimutati...

Bello(O),Rieur(O),Vidula(N) Pharmacogenomics None

...BRCA1/2, and AKT/PTEN are reviewed in relation to their corresponding therapeutic agents. Implementation challenges, pre...

Munir(A),Rizwan(M),Janbey(A) Curr Drug Targets 2026-04-15

...BRCA1, BRCA2, BARD1, PALB2, TP53, CHEK2). Lipid-based nanoparticles (LNPs) and polymeric nanoparticles (PNPs) were devel...

Pineda(B),Martinez-Pretel(JJ),Sanchez-Serr... Front Oncol None

...BRCA1, BRCA2 and TP53, which are associated with chemotherapy sensitivity. Olaparib, a PARP inhibitor, provides the grea...

Murthy(D),Seyhan(AA),den Hollander(P),Lu(S... Mol Aspects Med 2026-06-00

...BRCA1/2-mutant disease, and combination cytotoxic regimens such as NALIRIFOX in the metastatic setting. However, these a...

Kaufmann(NA),Oppelt(P),Grimm(C),Lastinger(... Arch Gynecol Obstet 2026-04-20

...BRCA1-positive patient undergoing prophylactic bilateral salpingo-oophorectomy and a patient with an incidental STIC fin...

Liu(S),Hu(H) Discov Oncol 2026-04-20

...BRCA1, BRCA2, and others. CONCLUSION: This report describes a breast tumor exhibiting concurrent features of AcCC and ma...